Acinetobacter infectious disease

Summary

Acinetobacter infectious disease (MONDO:0006635) is a disease and 11 clinical trials. Top therapeutic interventions include colistimethate sodium, colistin, and minocycline. A subtype of Moraxellaceae infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 11

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Acinetobacter infectious disease
Mondo ID	MONDO:0006635
EFO	EFO:1000792
MeSH	D000151
DOID	DOID:3091
UMLS	C0001139
MedGen	1299
Is cancer (heuristic)	no

Also known as: Acinetobacter caused disease or disorder · Acinetobacter disease or disorder · Acinetobacter infection · infection, Acinetobacter · infection, Mimae · infections, Acinetobacter · infections, Mimae · Mimae infection · Mimae infections

Disease family

This is a subtype of Moraxellaceae infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › gram-negative bacterial infections › Moraxellaceae infectious disease › Acinetobacter infectious disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 11.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	8
PHASE4	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02688322	PHASE4	COMPLETED	Pharmacodynamics Modeling to Optimize Dosage Regimens of Sulbactam in Patients With Acinetobacter Infections
NCT05586815	PHASE4	UNKNOWN	Efficacy of Colistin Monotherapy Versus Colistin Plus Minocycline for Carbapenem-Resistant A. Baumannii Infection
NCT04803708	PHASE1/PHASE2	COMPLETED	Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers
NCT00462579	Not specified	COMPLETED	Risk Factors for Carbapenem-resistant Acinetobacter Baumannii
NCT00524290	Not specified	COMPLETED	Multinational Study of Acinetobacter Bloodstream Infection: Clinical Outcomes and Global Epidemiology-PITT Protocol
NCT00524563	Not specified	COMPLETED	Clinical Outcomes and Global Epidemiology -Data Coordinating Center
NCT02482961	Not specified	COMPLETED	Impact of Plasma Levels of Colistin in Patients With Carbapenem Resistant Acinetobacter Baumannii Infection
NCT02573064	Not specified	COMPLETED	Impact of Treatment With Colistin on Mortality Bacteremia Multiresistant Acinetobacter Baumannii Sensitive Colistin in Patients Critical
NCT03622918	Not specified	COMPLETED	Colistin-rifampin Combination and Colistin Monotherapy in Extensively Drug-resistant Acinetobacter Baumannii
NCT05210387	Not specified	TERMINATED	Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections
NCT05880069	Not specified	UNKNOWN	Clinical Outcomes in Patients With Infection by Resistant Microorganism

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
COLISTIMETHATE SODIUM	4	4
COLISTIN	4	3
MINOCYCLINE	4	1
SULBACTAM	4	1
TIGECYCLINE	4	1
CHEMBL2221249	0	3
CHEMBL4793072	0	3
CHEMBL5411808	0	3
CHEMBL6151919	0	3
CHEMBL4071927	0	1
CHEMBL4754862	0	1